^
CANCER:

Small Lymphocytic Lymphoma





Show legend
Group by Gene:
zanubrutinib
ibrutinib
0
BTK inhibitor
pirtobrutinib
orelabrutinib
acalabrutinib
M7583
CD20 inhibitor
1
CD20 inhibitor
obinutuzumab
rituximab
2
Bcl2 inhibitor, CD20 inhibitor
venetoclax + obinutuzumab
venetoclax + rituximab
3
PI3Kδ inhibitor
idelalisib
4
CD52 inhibitor
alemtuzumab
5
PI3Kδ inhibitor, CD20 inhibitor
rituximab + idelalisib
6
CD52 inhibitor, CD20 inhibitor
rituximab + alemtuzumab
7
PD1 inhibitor
pembrolizumab
8
Bcl2 inhibitor, BTK inhibitor
venetoclax + ibrutinib
9
Bcl2 inhibitor
venetoclax
10
PD1 inhibitor, BTK inhibitor
pembrolizumab + ibrutinib
11
CD19-targeted CAR-T immunotherapy
lisocabtagene maraleucel
12
Alkylating agent
chlorambucil
13
CD19-targeted CAR-T immunotherapy, BTK inhibitor
ibrutinib + lisocabtagene maraleucel
obinutuzumab + acalabrutinib
14
BTK inhibitor, CD20 inhibitor
ibrutinib + rituximab
ibrutinib + obinutuzumab
obinutuzumab + zanubrutinib
15
MDM2 inhibitor, BTK inhibitor
acalabrutinib + KRT-232
PCR
R-CVAD
EPOCH-R
16
Chemotherapy
R-CHOP
BR
FCR
OFAR
17
T-lymphocyte cell therapy
T-lymphocyte cell therapy
18
BTK inhibitor, Chemotherapy
BR + ibrutinib
19
PI3Kδ inhibitor, Chemotherapy
BR + idelalisib
20
PI3Kγ inhibitor, PI3Kδ inhibitor
duvelisib
21
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
22
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
rituximab + lenalidomide
No biomarker
TP53 wild-type
TP53 mutation
TP53 deletion
TP53 mutation + Chr del(17p)
IGH mutation
BIRC3 mutation
CD20 positive
CD19 positive
ATM mutation
ALK positive
BTK C481
Chr del(17p)
Chr del(11)(q22.3)
Chr del(17)(p13.1)
Chr del(11q)